

Commercial/Healthcare Exchange PA Criteria

Effective: May 1, 2018

Prior Authorization: Steglujan

Products Affected: Steglujan (ertugliflozin/sitagliptin) tablet

Medication Description:

Steglujan (ertugliflozin/sitagliptin) has been approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) when treatment with both ertugliflozin and sitagliptin is appropriate.

Steglujan (ertugliflozin/sitagliptin) combines a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor with a sodiumglucose cotransporter-2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting SGLT2, the major transporter responsible for the reabsorption of filtered glucose from the kidney. The SGLT2 inhibitors are efficacious agents in reducing HbA1c, postprandial glucose, and fasting plasma glucose, as well as reducing systolic blood pressure and weight. DPP-4 inhibitors have modest glucose-lowering effects with HbA1c decrements of 0.5% to 1%. These agents are weight-neutral and have a low hypoglycemia risk when used as monotherapy or in conjunction with metformin.

Covered Uses: Type 2 diabetes mellitus (T2DM) in patients when treatment with both ertugliflozin and sitagliptin is appropriate.

Exclusion Criteria:

- 1. Pediatric patients
- 2. Severe renal impairment, end-stage renal disease (ESRD), or dialysis
- 3. Type 1 diabetes mellitus
- 4. Treatment of diabetic ketoacidosis

Required Medical Information:

- 1. Diagnosis
- 2. History of previous therapy tried/failed
- 3. Current medication therapy

Age Restrictions: 18 years of age or older.

Coverage Duration: 12 months

Other Criteria:

Diabetes Mellitus Type 2:

Approve Steglujan if the patient meets the following criteria (A, B, C, and D):

A) Patient has a diagnosis of Diabetes Mellitus type 2; **AND**B) Patient is at least 18 years of age or older; **AND**

- C) Patient is currently being treated with situaliptin OR saxagliptin; AND
- **D)** Patient is currently being treated with dapagliflozin OR canafliglozin



Last Res. January 16, 2020



References:

- 1. Steglujan [package insert]. Whitehouse Station, NJ; Merck; December 2017.
- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed February 23, 2018.
- 3. American Diabetes Association: Standards of Medical Care in Diabetes 2018. Available at: http://professional.diabetes.org/content/clinical-practice-recommendations. Accessed February 23, 2018.

Policy Revision history

Rev#	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	01/23/2020

